Show results for
Refine by
Glaucoma Suppliers In Australia
4 companies found
based inBrunswick, AUSTRALIA
Avania is an integrated global, full-service CRO with specialized expertise in medical device, novel technology, and combination products. They advance products from feasibility all the way through post-approval trials in analytics, clinical trials, ...
Preserving or restoring eyesight has the power to change a patient’s life. Avania’s ophthalmology team works with you to advance your important research that is necessary for better eye health. From medical technologies to medical ...
based inCottesloe, AUSTRALIA
Neuroscientific Biopharmaceuticals is an Australian public company (ASX:NSB) developing novel peptide-based pharmaceutical products that target a number of neurological disorders and diseases of the eye that have high unmet medical need. Our vision ...
Multiple indications with unmet medical need. “Our company goal is to create new products that reach their target in the brain and act as a protector against nerve cells injury. Currently, there are no approved drugs that can slow down or halt ...
based inCapelle aan den IJssel, NETHERLANDS
Topcon Corporation is a global leader in manufacturing of technology designed to address essential challenges society faces in healthcare, agriculture and infrastructure. Topcon specializes in developing optical, sensing and control solutions ...
Introducing automated OCT, true color fundus photography and automated OCT Angiography in one compact instrument. With the touch of a button, OCTA provides you instantaneous vascular structure information – from our world-renowned, multi-modal ...
based inSan Clemente, CALIFORNIA (USA)
Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. At Glaukos, our focus is to develop and lead the ...
iStent inject® W is indicated for use in conjunction with cataract surgery for the reduction of IOP in adult patients with mild to moderate primary open-angle ...